Richard J. Mead

Glutathione Oxidation in Cerebrospinal Fluid as a Biomarker of Oxidative Stress in Amyotrophic Lateral Sclerosis

This study measures glutathione oxidation in cerebrospinal fluid of ALS patients and healthy controls, finding elevated levels and correlations with disease progression and protein oxidation.

Comparison of AAV9-driven motor neuron transduction following different CNS-directed delivery methods in mice

This study compares AAV9-driven motor neuron transduction efficiency using different CNS delivery methods in mice, finding that unilateral ICV delivery provides the highest and most consistent transduction with minimal peripheral viral copies.

Artificial intelligence-augmented drug discovery identifies gefitinib as a potential treatment for ALS

This paper uses AI to identify gefitinib as a potential ALS treatment, showing it protects motor neurons and reduces TDP-43 fragments in vitro and in vivo.

M102, a combined NRF2 and HSF-1 activator for neuroprotection in amyotrophic lateral sclerosis.

M102, a dual NRF2/HSF1 activator, slows disease progression in 2 mouse models and exerts neuroprotection in human cellular models of ALS.

Maximising the translational potential of neurophysiology in amyotrophic lateral sclerosis: a study on compound muscle action potentials

This study compares compound muscle action potentials (CMAPs) in SOD1G93A mice and human ALS patients to identify translational alignment points for disease progression.

A cell-penetrant peptide blocking C9ORF72-repeat RNA nuclear export suppresses neurodegeneration

This paper develops a cell-penetrant peptide that blocks C9ORF72-repeat RNA nuclear export, reducing neurodegeneration in preclinical models of ALS and FTD.

Caudal-rostral progression of alpha motoneurone degeneration in the SOD1G93A mouse model of amyotrophic lateral sclerosis

The paper quantifies the caudal-rostral progression of alpha motoneurone degeneration in SOD1G93A mice, showing greater susceptibility in lumbar spinal cord regions.